Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial

Japanese RCT (n=150) reported greater baseline decreases in absolute ALT levels at 12 weeks with the 24 μg (mean −13 U/L vs +1 U/L; p=0.0007) and 12 μg lubiprostone groups (−12 U/L vs+1 U/L; p=0.0023) vs placebo.


Lancet Gastroenterology and Hepatology